Search details
1.
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Lancet Oncol
; 16(6): 704-15, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25925619
Results
1 -
1
de 1
1
Next >
>>